EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Methionine restriction plus vitamin B12 antagonism overcomes methionine independence for cancer therapy

Valentin Lacombe, Jade Aurrière, Adélie Mellinger, Salim Khiati, Nicolas Giachetti, Flavien Bessaguet, Sarah Bellal, Pascal Reynier, Franck Geneviève, Geoffrey Urbanski, Guy Lenaers

Cancer Letters · 2026-10 · 657 · 218723

DOI: 10.1016/j.canlet.2026.218723 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-10. Verfasst von Valentin Lacombe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Univ Angers, Inserm, CNRS, MITOVASC, Equipe MitoLab, SFR ICAT, Angers, F-49000, France; Service de Médecine interne et polyvalente, Centre Hospitalie…. Hauptthemen laut MEDLINE: Methionine, Vitamin B 12, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Réseau Sociétés d'Accélération du Transfert de Technologies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methionine dependence represents a well-known metabolic vulnerability in cancer. Despite promising preclinical results, methionine restriction is impaired by the presence of methionine-independent cancer cells. After confirming both inter- and intra-tumoral heterogeneity in methionine dependence, we demonstrate that "methionine-independent" cells are rather "methionine self-sufficient," relying on the vitamin B12 (B12)-dependent methionine synthase (MTR) to sustain growth without exogenous methionine, which renders them highly vulnerable to B12 deprivation. Dual methionine and B12 deprivation produced synergistic cytotoxicity, inhibiting proliferation and inducing apoptosis across multiple cancer types and primary tumor cells, while sparing fibroblasts. This synergy persisted under moderate nutrient restriction, supporting translational potential. Moreover, dual therapy prevented the adaptive metabolic shift seen with methionine deprivation alone, avoiding rebound proliferation and resistance. In vivo, a methionine-restricted diet plus a synthesized B12 antagonist significantly suppressed growth of methionine-independent pancreatic xenografts without hematologic toxicity. These findings uncover a selective, synergistic anticancer strategy targeting methionine self-sufficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethionineVitamin B 12NeoplasmsAnimalsHumans5-Methyltetrahydrofolate-Homocysteine S-MethyltransferaseCell ProliferationCell Line, TumorApoptosisXenograft Model Antitumor AssaysMiceFemale

Stichwörter der Autor:innen

Dietary restrictionMethionineMethionine synthaseNeoplasmsVitamin B12

Substanzen

MethionineVitamin B 125-Methyltetrahydrofolate-Homocysteine S-MethyltransferaseMTR protein, human

Autor:innen und Institutionen

  • Univ Angers, Inserm, CNRS, MITOVASC, Equipe MitoLab, SFR ICAT, Angers, F-49000, France; Service de Médecine interne et polyvalente, Centre Hospitalier du Haut-Anjou, Château-Gontier, France; Service de Médecine interne…
  • Univ Angers, Inserm, CNRS, MITOVASC, Equipe MitoLab, SFR ICAT, Angers, F-49000, France.
  • Univ Angers, Inserm, CNRS, MITOVASC, Equipe MitoLab, SFR ICAT, Angers, F-49000, France; Service de Médecine interne et polyvalente, Centre Hospitalier du Haut-Anjou, Château-Gontier, France.
  • Univ Angers, Inserm, CNRS, MITOVASC, Equipe MitoLab, SFR ICAT, Angers, F-49000, France; Service de Médecine interne et immunologie clinique, Centre Hospitalier Universitaire d'Angers, Angers, France.
  • Univ Angers, Inserm, CNRS, MITOVASC, Equipe Carme, SFR ICAT, Angers, F-49000, France.
  • Département de Pathologie cellulaire et tissulaire, Centre Hospitalier Universitaire d'Angers, Angers, France.

Förderung

  • Réseau Sociétés d'Accélération du Transfert de Technologies

Zitieren

APA

Lacombe, V., Aurrière, J., Mellinger, A., Khiati, S., Giachetti, N., Bessaguet, F., Bellal, S., Reynier, P., Geneviève, F., Urbanski, G., & Lenaers, G. (2026). Methionine restriction plus vitamin B12 antagonism overcomes methionine independence for cancer therapy. Cancer Letters, 657, 218723. https://doi.org/10.1016/j.canlet.2026.218723

Vancouver

Lacombe V, Aurrière J, Mellinger A, Khiati S, Giachetti N, Bessaguet F, et al. Methionine restriction plus vitamin B12 antagonism overcomes methionine independence for cancer therapy. Cancer Letters. 2026;657:218723. doi:10.1016/j.canlet.2026.218723

BibTeX
@article{Lacombe2026,
  author = {Lacombe, Valentin and Aurrière, Jade and Mellinger, Adélie and Khiati, Salim and Giachetti, Nicolas and Bessaguet, Flavien and Bellal, Sarah and Reynier, Pascal and Geneviève, Franck and Urbanski, Geoffrey and Lenaers, Guy},
  title = {Methionine restriction plus vitamin B12 antagonism overcomes methionine independence for cancer therapy},
  journal = {Cancer Letters},
  year = {2026},
  volume = {657},
  pages = {218723},
  doi = {10.1016/j.canlet.2026.218723}
}
Kostenlos starten →